Clinical Trial

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

Name: Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients — clinical trial record (NCT06931080)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-09.

Trial Details

NCT Number	NCT06931080
Lead Sponsor	Otsuka Pharmaceutical Co., Ltd.
Conditions	Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment	630 participants
Start Date	2025-04-30
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-03